We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Daniel Rubin

Daniel J. Rubin MD, MSc, FACE

Professor of Medicine; Director of Clinical Research; Deputy Chief, Section of Endocrinology, Diabetes, and Metabolism, Lewis Katz School of Medicine at Temple University; Chair, Glycemic Control Taskforce, Temple University Hospital, Philadelphia, Pennsylvania

Dr. Rubin is Professor of Medicine in the Section of Endocrinology, Diabetes, and Metabolism at the Lewis Katz School of Medicine at Temple University and a Fellow of the American College of Endocrinology. He earned a Master of Science in Epidemiology with a concentration in Biostatistics at the Boston University School of Public Health. At Temple University Hospital, he serves as Chair of the Glycemic Control Taskforce. His research focuses on inpatient diabetes management and hospital readmissions among patients with diabetes. He is currently funded by an NIH/NIDDK K23 Award on predicting and preventing readmissions among diabetes patients.


Financial disclosures: Dr. Rubin has received research grants from AstraZeneca and Boehringer Ingelheim in the past 12 months. (07/22/17)